Icagen, a subsidiary of OmniAb, specializes in ion channel drug discovery, leveraging its advanced technology platform to develop targeted therapeutics. The company collaborates with globally recognized pharmaceutical and biotech firms to advance high-value ion channel and transporter drug discovery programs. Icagen's platform combines novel reagent generation, advanced biophysical analysis, and cutting-edge in silico drug discovery tools to address challenging ion channel targets. The business operates in the pharmaceutical and biotechnology markets, serving clients who require specialized drug discovery capabilities. Icagen generates revenue through collaborative partnerships and service agreements with its clients, providing them with innovative solutions to accelerate their drug discovery processes.

Keywords: ion channel, drug discovery, therapeutics, pharmaceutical, biotech, reagent generation, biophysical analysis, in silico tools, transporter targets, collaborative partnerships.